The Early Notification to Act, Control, and Treat (ENACT) program aims to disrupt the traditional diagnostic approach to healthcare by leveraging transformational technologies that provide actionable health information in real-time. ENACT supports advanced data analytics and algorithm development coupled with innovative disease detection modalities to alert individuals of an infection ahead of the onset of obvious symptoms; provide patients’ continuous health status details to medical care providers for triage and early treatment; and prognosticate individual and population-wide health outcomes. In partnership with private sector and academic partners across the nation, ENACT’s technological solutions deliver real-time health information to empower the individual, public health organizations, and the health-care provider to rapidly act, control, and treat infectious diseases.
Sepsis is one of the country’s most urgent systemic health threats. Each year, more than 1.7 million people in the U.S. develop sepsis and 270,000 adult Americans die.1 In addition to the toll on health, sepsis costs over $62 billion each year.2 Sepsis can occur when any infection – such as drug-resistant bacteria or influenza – triggers a chain reaction throughout the body. It has a high potential to arise consequent to any health security threat. In order to fully protect Americans and save lives, the BARDA DRIVe Solving Sepsis program aims to reduce the incidence, morbidity, mortality, and economic burden of sepsis by investing in key strategic areas. The program is catalyzing technological approaches along the sepsis patient continuum to empower both the patient and the healthcare provider with a focus on innovative technologies that specifically address sepsis.
The Solving Sepsis program is committed to combating sepsis.
DRIVe will seek a limited number of additional extremely bold, radical, and disruptive innovative solutions that will have the ability to transform health security. These include – but are not limited to – creating universal treatment options for broad classes of pathogens, ensuring access to life-saving medical countermeasures, and transforming medical countermeasure development by eradicating animal testing. For more information on these additional impact areas, see the DRIVe EZ Broad Agency Announcement.